Nektar Therapeutics (NKTR) Scheduled to Post Earnings on Tuesday
Nektar Therapeutics (NASDAQ:NKTR) will be posting its quarterly earnings results after the market closes on Tuesday, February 27th. Analysts expect Nektar Therapeutics to post earnings of ($0.33) per share for the quarter.
Nektar Therapeutics (NASDAQ NKTR) opened at $83.43 on Tuesday. The stock has a market cap of $13,140.00, a PE ratio of -117.51 and a beta of 2.04. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a 1 year low of $12.50 and a 1 year high of $99.02.
In related news, Director Christopher A. Kuebler sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total value of $1,759,800.00. Following the transaction, the director now owns 70,500 shares of the company’s stock, valued at approximately $4,135,530. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Howard W. Robin sold 83,333 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total transaction of $4,640,814.77. Following the completion of the transaction, the chief executive officer now directly owns 272,768 shares in the company, valued at approximately $15,190,449.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 196,666 shares of company stock worth $12,718,923. 5.44% of the stock is owned by insiders.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.